Compare Huntington Bancshares Incorporated (HBAN) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Bancshares Incorporated vs Regeneron Pharmaceuticals Inc — how do they compare? Huntington Bancshares Incorporated trades at $15.41 (market cap $31.04B), while Regeneron Pharmaceuticals Inc trades at $740 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.5× Huntington Bancshares Incorporated's market cap, and Huntington Bancshares Incorporated pays the higher dividend (4.04%). Which is the better fit depends on your goals — on Pluang, investors hold Huntington Bancshares Incorporated for 52 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| HBAN | REGN | |
|---|---|---|
Market Cap | $31.04B | $76.14B |
Volume | 23,864,172 | 500,239 |
Sector | Financials | Health |
52-Week High | $19.27 | $852.03 |
52-Week Low | $15.02 | $557.73 |
Typical Hold Time | 52 Days | 107 Days |
Enterprise Value | $49.57B | $70.85B |
Dividend Yield | 4.04% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Huntington Bancshares (HBAN) trades at $15.17, down 1.04% on the day, with a bearish technical signal. The company reported mixed quarterly earnings, missing in Q4 2025 and Q2 2026 but beating in Q1 2026, while revenue grew to $8.13B in 2025. Analyst consensus is split evenly between Buy and Hold, with a $19.60 price target suggesting upside. Recent news highlights margin pressures from higher interest rates and a revised 2027 outlook.
HBAN offers value with a P/E of 11.82 and pays a dividend, but faces headwinds from net interest margin compression and loan growth challenges. The stock's near-term performance hinges on Q3 2026 earnings and management's ability to navigate rate environment pressures.
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
